Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 4 molecules, respectively.
Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 4 molecules, respectively.
Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
Altum Pharmaceuticals Inc
Antiva Biosciences Inc
Bioleaders Corp
Brooklyn ImmunoTherapeutics LLC
CEL-SCI Corp
Douglas Pharmaceuticals Ltd
Elicio Therapeutics
Genexine Inc
GenoLac BL Corp
Hefei Ruichengsheng Biotechnology Co Ltd
Inovio Pharmaceuticals Inc
KinoPharma Inc
Novan Inc
Papivax LLC
PDS Biotechnology Corp
Redbiotec AG
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Institute of Biological Products Co Ltd
THEVAX Genetics Vaccine USA Inc
Transgene SA
Vaccibody AS
Vaxart Inc
ViciniVax BV
Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
(bizalimogene ralaplasmid + mavilimogene ralaplasmid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(lopinavir + ritonavir) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABI-1968 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSILSB-710c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSPGAC-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Human Papillomavirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target HPV Protein E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efineptakin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLBL-101c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus (9 valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 16, 18, 52, 58] (tetravalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IGMKK-16E7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IRX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multikine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-721689 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RKP-00156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RONC-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tipapkinogene sovacivec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVGV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia And HPV Associated Head And Neck Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-1016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VED-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXAHPV-16.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WH-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WH-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZFN-603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZFN-758 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
Featured News & Press Releases
Dec 03, 2019: PDS Biotechnology to present at the 12th Annual LD Micro Main Event
Nov 25, 2019: PDS Biotechnology to present at the World Vaccine & Immunotherapy Congress West Coast 2019
Nov 06, 2019: PDS Biotechnology accepted for oral presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting
Oct 01, 2019: PDS Biotechnology prioritizes development of PDS0101 in advanced cancers following promising phase 1 clinical outcome data
Sep 19, 2019: PDS Biotechnology reports clinical data for its novel immunotherapy PDS0101 in follow up to phase 1 human trial
Jun 26, 2019: Inovio completes enrollment of VGX-3100 phase 3 trial (reveal 1) for the treatment of HPV-related cervical pre-cancer
Jun 05, 2019: Peer-reviewed publication confirms the potential of Transgene' TG4001
May 06, 2019: Inovio receives European Medicines Agency Certification for quality and non-clinical data for its Phase 3 product, VGX-3100
Apr 17, 2019: Inovio's phase 3 HPV immunotherapy selected as "Best Therapeutic Vaccine" at World Vaccine Congress
Apr 03, 2019: Therapy completely clears HPV in one-third of cervical precancers
Mar 25, 2019: Positive 12-month results from phase IIa clinical study in high grade cervical dysplasia provides proof-of-concept for Vaccibody’s immunotherapy platform and lead candidate VB1O.16
Feb 27, 2019: vaccibody as to present data on vb10.16 at upcoming American Association for Cancer Research Annual Meeting
Dec 06, 2018: Study tests new vaccine for precancerous cervical cells
Apr 26, 2018: Vaccibody Announces Strong Killer T Cell Responses (Cd8+) In Vb10.16 Vaccinated Patients Further Strengthening The Strong Potential Of Their Vaccine Technology Platform; Presenting At European Neoantigen Summit Amsterdam
Feb 14, 2018: IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
Altum Pharmaceuticals Inc
Antiva Biosciences Inc
Bioleaders Corp
Brooklyn ImmunoTherapeutics LLC
CEL-SCI Corp
Douglas Pharmaceuticals Ltd
Elicio Therapeutics
Genexine Inc
GenoLac BL Corp
Hefei Ruichengsheng Biotechnology Co Ltd
Inovio Pharmaceuticals Inc
KinoPharma Inc
Novan Inc
Papivax LLC
PDS Biotechnology Corp
Redbiotec AG
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Institute of Biological Products Co Ltd
THEVAX Genetics Vaccine USA Inc
Transgene SA
Vaccibody AS
Vaxart Inc
ViciniVax BV
Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
(bizalimogene ralaplasmid + mavilimogene ralaplasmid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(lopinavir + ritonavir) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABI-1968 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSILSB-710c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSPGAC-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Human Papillomavirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target HPV Protein E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efineptakin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLBL-101c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus (9 valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 16, 18, 52, 58] (tetravalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IGMKK-16E7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IRX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multikine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-721689 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RKP-00156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RONC-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tipapkinogene sovacivec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVGV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia And HPV Associated Head And Neck Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-1016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VED-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXAHPV-16.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WH-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WH-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZFN-603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZFN-758 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
Featured News & Press Releases
Dec 03, 2019: PDS Biotechnology to present at the 12th Annual LD Micro Main Event
Nov 25, 2019: PDS Biotechnology to present at the World Vaccine & Immunotherapy Congress West Coast 2019
Nov 06, 2019: PDS Biotechnology accepted for oral presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting
Oct 01, 2019: PDS Biotechnology prioritizes development of PDS0101 in advanced cancers following promising phase 1 clinical outcome data
Sep 19, 2019: PDS Biotechnology reports clinical data for its novel immunotherapy PDS0101 in follow up to phase 1 human trial
Jun 26, 2019: Inovio completes enrollment of VGX-3100 phase 3 trial (reveal 1) for the treatment of HPV-related cervical pre-cancer
Jun 05, 2019: Peer-reviewed publication confirms the potential of Transgene' TG4001
May 06, 2019: Inovio receives European Medicines Agency Certification for quality and non-clinical data for its Phase 3 product, VGX-3100
Apr 17, 2019: Inovio's phase 3 HPV immunotherapy selected as "Best Therapeutic Vaccine" at World Vaccine Congress
Apr 03, 2019: Therapy completely clears HPV in one-third of cervical precancers
Mar 25, 2019: Positive 12-month results from phase IIa clinical study in high grade cervical dysplasia provides proof-of-concept for Vaccibody’s immunotherapy platform and lead candidate VB1O.16
Feb 27, 2019: vaccibody as to present data on vb10.16 at upcoming American Association for Cancer Research Annual Meeting
Dec 06, 2018: Study tests new vaccine for precancerous cervical cells
Apr 26, 2018: Vaccibody Announces Strong Killer T Cell Responses (Cd8+) In Vb10.16 Vaccinated Patients Further Strengthening The Strong Potential Of Their Vaccine Technology Platform; Presenting At European Neoantigen Summit Amsterdam
Feb 14, 2018: IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Altum Pharmaceuticals Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Antiva Biosciences Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Brooklyn ImmunoTherapeutics LLC, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Douglas Pharmaceuticals Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Elicio Therapeutics, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by GenoLac BL Corp, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by KinoPharma Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Novan Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Papivax LLC, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Redbiotec AG, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaxart Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by ViciniVax BV, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H2 2019
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Altum Pharmaceuticals Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Antiva Biosciences Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Brooklyn ImmunoTherapeutics LLC, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Douglas Pharmaceuticals Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Elicio Therapeutics, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by GenoLac BL Corp, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by KinoPharma Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Novan Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Papivax LLC, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Redbiotec AG, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaxart Inc, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by ViciniVax BV, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H2 2019
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
Altum Pharmaceuticals Inc
Antiva Biosciences Inc
Bioleaders Corp
Brooklyn ImmunoTherapeutics LLC
CEL-SCI Corp
Douglas Pharmaceuticals Ltd
Elicio Therapeutics
Genexine Inc
GenoLac BL Corp
Hefei Ruichengsheng Biotechnology Co Ltd
Inovio Pharmaceuticals Inc
KinoPharma Inc
Novan Inc
Papivax LLC
PDS Biotechnology Corp
Redbiotec AG
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Institute of Biological Products Co Ltd
THEVAX Genetics Vaccine USA Inc
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
Altum Pharmaceuticals Inc
Antiva Biosciences Inc
Bioleaders Corp
Brooklyn ImmunoTherapeutics LLC
CEL-SCI Corp
Douglas Pharmaceuticals Ltd
Elicio Therapeutics
Genexine Inc
GenoLac BL Corp
Hefei Ruichengsheng Biotechnology Co Ltd
Inovio Pharmaceuticals Inc
KinoPharma Inc
Novan Inc
Papivax LLC
PDS Biotechnology Corp
Redbiotec AG
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Institute of Biological Products Co Ltd
THEVAX Genetics Vaccine USA Inc
